New drug cocktail tested for ovarian cancer maintenance
NCT ID NCT07000344
First seen May 02, 2026 · Last updated May 24, 2026 · Updated 5 times
Summary
This study looked at whether adding a third drug (fluzoparib) to a two-drug combination (apatinib and letrozole) helps control recurrent ovarian cancer longer. It included adults with a specific type of ovarian cancer that had responded to prior treatment. The study was stopped early and only enrolled 5 people, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100021, China
Conditions
Explore the condition pages connected to this study.